Novartis has come up short in its bid to expand its blockbuster drug Cosentyx to an autoimmune disease whose only biologic treatment options are an old Roche drug and the biosimilars that have ...

FDA approval based on robust Phase III data in which Cosentyx ® (secukinumab) showed rapid relief from symptoms of hidradenitis suppurativa (HS) as early as Week 2 1 As the only IL-17A inhibitor ...

The Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) injections for treating various inflammatory conditions in adults and, in some cases, children. Cosentyx may treat moderate ...

EAST HANOVER, N.J., Oct. 6, 2023 /PRNewswire/ -- Novartis, a global leader in immuno-dermatology and rheumatology, announced today that the US Food and Drug Administration (FDA) has approved an ...

Cosentyx, an autoimmune disease therapy that cost the healthcare industry $7.7 billion in 2024, will be offered at a 55% discount beginning in November. The drug’s manufacturer, Novartis, said Sept.

It’s also available as a liquid solution in a single-dose vial to administer as an intravenous (IV) infusion. Only a healthcare professional can administer this form. Your healthcare professional can ...

The Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) injections to treat several inflammatory conditions. Adults and certain children can receive this medication to treat ...

Biologics are complex medications produced through biological processes or from living organisms such as proteins and genes. Biosimilars are what they sound like — similar to, but not the same as, an ...